Open AccessOxcarbazepine monotherapy in children with benign epilepsy with centrotemporal spikes improves quality of life
Author(s) -
Wan-Ting Liu,
Xiuxian Yan,
Dazhi Cheng,
Han-Zi Zhang,
Ning Ding,
Keming Xu,
Xinlin Zhou,
Qian Chen
Publication year - 2020
Publication title -
chinese medical journal/chinese medical journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.537
H-Index - 63
eISSN - 2542-5641
pISSN - 0366-6999
DOI - 10.1097/cm9.0000000000000925
Subject(s) - oxcarbazepine , epilepsy , psychosocial , anxiety , neuropsychology , quality of life (healthcare) , cognition , psychology , audiology , amisulpride , medicine , schizophrenia (object oriented programming) , psychiatry , pediatrics , antipsychotic , carbamazepine , psychotherapist
Benign epilepsy with centrotemporal spikes (BECTS) is the most common type of childhood idiopathic focal epilepsy. BECTS is associated with pervasive cognitive deficits and behavior problems. While seizures can be easily controlled, it is crucial to select anti-epileptic drugs that do not impair cognition, do not cause psychosocial effects, and improve the quality of life. Previous studies showed effects of oxcarbazepine (OXC) monotherapy on the cognitive and psychosocial profiles of patients with BECTS. Here, we studied the effects of OXC monotherapy on the neuropsychologic profiles and quality of life in patients with BECTS in China.